Global Nanoparticle Formulation Market 2023 to 2035: Lipid Nanoparticle Formulation is Driving Partnership Activity
DUBLIN, July 4, 2023 /PRNewswire/ -- The "Nanoparticle Formulation Market 2023-2035" report has been added to ResearchAndMarkets.com's offering.
The global nanoparticle formulation market was estimated to be worth USD 5.1 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 9.4% during the forecast period.
This report features an extensive study of the current market landscape, market size and future opportunities associated with the nanoparticle formulation technologies and services market, during the given forecast period. Further, the report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the nanoparticle formulation market are briefly discussed below.
Over the years, nanoparticles have emerged as a versatile drug delivery system for the controlled, targeted delivery of therapeutics for the treatment of several diseases. Owing to their inherent properties, such as small size, multifunctional behavior and surface tailorability, these novel nanoparticle drug delivery systems confer several advantages over the conventional drug delivery systems.
The ongoing advancements in nanoparticle technology have paved way for the development of safe and effective nano-based drugs with improved treatment specificity, stability, water solubility, and high penetration and retention time. In addition, nanoparticles are widely adopted in other healthcare-associated segments, such as diagnostic assays, dentistry, tissue-engineered constructs and medical imaging.
However, nanoparticle development and nanoparticle formulation is a complex and cost-intensive process. The nanoparticles need to be engineered through advanced nanoparticle formulation and nanoparticle manufacturing techniques that require specialized technical expertise.
Therefore, researchers and drug developers are actively relying on contract service providers having the technical expertise and nanoparticle technology to develop and formulate the desired nanoparticles. Further, driven by the growing demand for nanoparticle-based therapeutics, the nanoparticle formulation market is anticipated to witness substantial growth during the forecast period.
Rising Interest in Nanoparticle-based Vaccines to Drive Nanoparticle Formulation Market
High mortality and morbidity rates caused due to coronavirus infection prompted the researchers and drug developers to develop safer, effective Covid vaccines. They are actively investigating the role of mRNA vaccines for the prevention and treatment of this life-threatening disease. The use of nanoparticles in vaccines contribute to the overall immunomodulatory properties, making them suitable candidates for the formulation of vaccines.
Lately, mRNA-LNP vaccines have demonstrated their potential as prophylactic Covid vaccines. It is interesting to highlight that, in 2020, Pfizer-BioNTech entered into an agreement with Acuitas Therapeutics to license Acuitas Therapeutic's lipid nanoparticle formulation technology to develop mRNA Covid vaccines. Further, in January 2022, both the companies expanded their agreement for the utilization of LNP technology in order to develop various vaccines and therapeutics.
Benefits of Formulating Drugs with Nanoparticles
The growing interest in using nanoparticles for therapeutic purposes can be attributed to their ability to encapsulate multiple drugs, enhanced drug bioavailability and protection from physiological barriers. The pharmaceutical industry has witnessed a steady rise in the number of approved drugs based on nanoparticle formulations. These nanopharmaceuticals can serve both as the delivery vehicle and therapeutic agent to aid in the treatment of a variety of disease conditions, including cancer, cardiovascular disorders, neurological disorders and infectious diseases.
In case of cancer, nanoparticles are being developed to increase the permeability and retention of chemotherapeutic agents and to aid in the delivery of both diagnostic and therapeutic agents. In 2018, the European Medicines Agency (EMA) approved Vyxeos (developed by Jazz Pharmaceuticals) for the treatment of acute myeloid leukemia. The drug is a LNP-based nanoformulation that has high circulation time in bone marrow.
Lipid Nanoparticle Formulation is Driving the Partnership Activity in the Overall Nanoparticle Formulation Market
Several stakeholders have been forging alliances with other industry / non-industry players in nanoparticle formulation market for technology licensing, research and development and product development purposes. It is worth highlighting that, since 2018, over 160 strategic partnerships have been inked in the nanoparticle formulation industry.
Owing to several advantages of lipid nanoparticles in therapeutics, the stakeholders are also acquiring other industry players specializing in various aspects of lipid nanoparticle formulation in order to expand their capabilities and build a comprehensive product / service portfolio. In February 2022, Merck acquired Exelead, a biopharmaceutical CDMO, to enhance its LNP formulation capabilities and operate as a one-stop-shop in the LNP formulation market.
At present, more than 40 companies engaged in providing lipid nanoparticle formulation service. Examples of top players engaged in this market (which have also been captured in this report) include BOC Sciences, CordenPharma, Curia, Emergent CDMO and Fujifilm.
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. TECHNOLOGY LANDSCAPE
5. SERVICE PROVIDERS LANDSCAPE
6. TECHNOLOGY COMPETITIVENESS ANALYSIS
7. COMPANY COMPETITIVENESS ANALYSIS
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Ascension Sciences
8.2.1. Company Overview
8.2.2. Technology Portfolio
8.2.3. Service Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. DIANT Pharma
8.3.1. Company Overview
8.3.2. Technology Portfolio
8.3.3. Service Portfolio
8.3.4. Recent Developments and Future Outlook
8.4. ExonanoRNA
8.4.1. Company Overview
8.4.2. Technology Portfolio
8.4.3. Service Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. Nanoform
8.5.1. Company Overview
8.5.2. Technology Portfolio
8.5.3. Service Portfolio
8.5.4. Recent Developments and Future Outlook
8.6. NanoVation Therapeutics
8.6.1. Company Overview
8.6.2. Technology Portfolio
8.6.3. Service Portfolio
8.6.4. Recent Developments and Future Outlook
8.7. NanoVelos
8.7.1. Company Overview
8.7.2. Technology Portfolio
8.7.3. Service Portfolio
8.7.4. Recent Developments and Future Outlook
8.8. NTT Biopharma
8.8.1. Company Overview
8.8.2. Technology Portfolio
8.8.3. Service Portfolio
8.8.4. Recent Developments and Future Outlook
8.9. Organoid-X BioTech
8.9.1. Company Overview
8.9.2. Technology Portfolio
8.9.3. Service Portfolio
8.9.4. Recent Developments and Future Outlook
8.10. Vaxinano
8.10.1. Company Overview
8.10.2. Technology Portfolio
8.10.3. Service Portfolio
8.10.4. Recent Developments and Future Outlook
9. PARTNERSHIPS AND COLLABORATIONS
10. PATENT ANALYSIS
11. NANOPARTICLE EVALUATION FRAMEWORK
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13. CASE STUDY: TECHNOLOGY LICENSING DEALS
14. CONCLUSION
15. EXECUTIVE INSIGHTS
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/y3rtzs
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
Share this article